Participating Companies

Angiocrine Bioscience
(Private) Developing technologies out of Weill Cornell focused on regeneration of lungs, tendons, cartilage, and liver as well as discovery programs for other tissue types. First generation programs are autologous genetically-modified products, designed for fast entry into clinic and commercialization with a proprietary manufacturing system. [more information]

Columbia University
Columbia University is one of the world's most important centers of research and a distinctive and distinguished learning environment. [more information]

Dana Farber Cancer Institute
[more information]

Jefferson University & Hospitals
[more information]

Kiadis Pharma N.V.
[KDS-AMS]
NK-cell platform administered as adjunct I-O on top of HSCT. Launched FIH POC trial in r/r AML patients (Feb 2020); set to launch additional HSCT trial later in 2020 w/interim data exp 2021. Presenting new data on ex-vivo FC21 expanded NK-cell therapy in 13 patients at EBMT in 2020. Established POC in 37 patients total. [more information]

Lineage Cell Therapeutics Inc.
[LCTX]
$369 MM MCap
Cell therapy company with 3 clnical programs 1) OpRegen, an RPE transplant therapy in Ph1/2a development for the treatment of dry-AMD. 2) OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries with Orphan and RMAT designations. 3) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in a Ph 1 for NSCLC conducted by CRUK. [more information]

NeuroRx
Leading Relief Therapeutics Ph 2 trial of Aviptadil to treat COVID-19 induced ARDS in the US. In Phase 3 with readout expected mid-January 2021. Also developing first Glx targeted antidepressant to address suicidality in bipolar depression. NRX-101 is in Ph 2b/3 development, (Breakthrough Designation, SPA and Fast Track Designation by FDA) for Severe Bipolar Depression in pts w Acute Suicidal Ideation and Behavior. [more information]

PharmaMar SA
[PHM:ES]
Revenue generating with marine-derived and novel MoA oncology products. Yondelis (soft tissue sarcoma and ovarian cancer) commercialized with direct sales-force in EU and partnership in US with Janssen. Signed licensing agreement with Jazz Pharma for lurbinectedin in the US - upfront payment of $200M, $100mm on approval and up to $550M sales milestones. [more information]

Targovax
[TRVX]
Preliminary Ph1b data of OV ONCOS-102+chemo in mesothelioma results: combo mPFS=8.4 mos. vs. control mPFS=6.8 mos.; 1L pts mPFS-8.9 mos. Upcoming milestones: updated clinical & immune data in Ph2 mesothelioma (1H20); preclinical data on next-gen OV w/ double transgenes (1H20); and clinical data from Ph1 melanoma study, part 2 with extended dosing (2H20). [more information]

University of British Columbia
The primary goal of the endowment is to provide financial returns to support the university's academic mission and to further UBC's vision to create a learning environment that fosters positive global citizenship. The goal of the UBC endowment is to support the university's academic mission in perpetuity. [more information]

White & Case LLP
The firm’s life sciences capabilities span strategic patent counseling, complex licensing and collaboration agreements, capital markets and M&A in the US, EU and globally. The firm has been helping life sciences access the capital markets in this challenging time, most recently representing the underwriters in this week’s successful $125M equity offering by Kura Oncology. [more information]